Background: Molecular signaling events associated with the necroinflammatory changes in nonalcoholic steatohepatitis (NASH) are not well understood.
INTRODUCTION
N ON-ALCOHOLIC FATTY LIVER disease (NAFLD) links chronic aberrant metabolism to structural changes in the liver, varying from increased fat deposition (steatosis) to potential cirrhosis. Although insulin resistance is the main driver of NASH, the inflammatory subtype of NAFLD, several other factors also have been implicated as contributory. These include genetic predisposition, 1 hepatic adenosine triphosphate content, 2, 3 redox state, 4, 5 gut-derived endotoxins, 6, 7 hormone exposure, 8, 9 innate immunogenic response 10, 11 and lipid content, composition, and zonation. 12 Given the presence of steatosis in NAFLD, much attention has been paid to lipid handling and the development of lipotoxic species as contributors to the development of non-alcoholic steatohepatitis (NASH). A more thorough understanding of the collective metabolic changes associated with NAFLD progression is needed to understand the mechanism of development of NASH.
Quantitative proteomics profiling has been used to differentiate protein expression within the disease spectrum of NAFLD. [13] [14] [15] [16] [17] [18] Serum proteomic profiling studies have reported remarkably few protein expression differences between different liver histologies ranging from no differences, 16 to increased hemoglobin expression with NASH, 15, 17 to alterations in pathways mediating immune responses, coagulation, cellular and extracellular matrix structure, and function. 13 Miller et al. utilized a labeled Protein post-translational modifications (PTMs), 22 such as phosphorylation, oxidation, ubiquitination, acetylation, acylation, sulfation, and glycosylation elicit different functional consequences that determine protein stability, degradation, and protein-protein interactions. 23 Phosphorylation, mediated through the addition and removal of phosphate groups by kinases and phosphatases, respectively, is among the most prevalent and dynamic of PTM and is most frequently found on hydroxyl-containing amino acids such as serine (Ser), threonine (Thr), and tyrosine (Tyr) and is central to metabolic pathway signaling. Phosphoproteomics, or the large-scale determination of protein phosphorylation status, can be used to characterize and compare a variety of disease states, but has been applied to NAFLD in only a handful of studies. Younossi et al. 24 described protein phosphorylation differences in visceral adipose tissue to be involved in the pathogenesis of NASH but thus far there have been few studies examining large-scale differences in protein phosphorylation in human liver.
The purpose of this study was to discern the differences in global phosphorylation profiles 25 differentiating SS from NASH. Our findings indicate that the progression from SS to NASH involves multiple phosphoproteomic pathways primarily involving carbohydrate metabolism, gastrointestinal diseases, and RNA post-transcriptional modifications. When applying stringent criteria for inclusion we identified 12 phosphorylation sites that differ significantly among the NAFLD cohorts.
METHODS

Subjects
C
LASS III OBESE women (n = 24; age, 26-59 years) were recruited at Vanderbilt (Nashville, TN, USA). Eight subjects with an established histologic diagnosis of SS, eight with NASH, and eight with normal (NOR) liver histology were selected. Exclusion criteria included presence of viral hepatitis, autoimmune hepatitis, hemochromatosis, significant alcohol use, concurrent infections, active cancer diagnosis within 5 years, glycosylated hemoglobin A1C >7.0, and use of antidiabetic drugs. The study protocol was approved by the institutional review board (#090647) and registered at ClinicalTrials.gov (NCT00983463). Wedge liver biopsies of the left lateral lobe were collected at the time of laparoscopic Roux-en-Y gastric bypass (RYGB). The presence of steatosis, ballooning, fibrosis, and inflammation were determined by a hepatopathologist from two independent histology specimens using the NAFLD activity score (NAS). 26 The definition of SS is histologic evidence of ≥5% lipid deposition within the liver parenchyma without features of steatohepatitis. The definition of steatohepatitis includes steatosis as defined above, but with features of inflammation, ballooning, and/or fibrosis in accordance with Kleiner et al.
26
Protein isolation and in-solution trypsin digestion
Portions of frozen human liver were homogenized and solubilized as previously described. 25 Briefly, 100-mg portions of frozen human liver were homogenized using a polytron homogenizer on maximum speed for 30 s on ice in MPER reagent (Pierce, Rockford, IL, USA) containing (final concentrations) 2 mM Na 3 VO 4 , 10 mM NaF, 1 mM sodium pyrophosphate, 1 mM ammonium molybdate, 250 μM phenylmethylsulphonyl fluoride, 10 μg/mL leupeptin, and 10 μg/mL aprotinin. Homogenates were allowed to sit for 30 min prior to centrifugation at 12 000 g for 15 min at 4°C to precipitate insoluble material. One milligram of soluble protein (concentration determined by the Bio-Rad DC Protein Assay; Hercules, CA, USA) was used for phosphopeptide enrichment. To prepare tryptic peptides for enrichment, aliquots of soluble protein from each sample homogenate were diluted up to 100 μL with 1 M Tris-HCl, pH 8.0, prior to addition of 100 μL trifluoroethanol. The samples were then reduced by addition of 2 μL of 0.5 M (tris(2-carboxyethyl)phosphine) for 1 h at room temperature, and alkylated with 4 μL of 500 mM iodoacetamide for 30 min in the dark at room temperature. Samples were diluted 10-fold with 100 mM Tris-HCl, pH 8.0, to reduce the solution to 5% trifluoroethanol, and digested overnight at 37°C with proteomics-grade trypsin (Sigma Chemical Co., St. Louis, MO, USA) at a ratio of 1:25 enzyme : protein. The resulting peptides were then desalted by solid-phase extraction (Sep-pak Light C18 cartridges, WAT023501; Waters Corporation, Milford, MA, USA). Digested samples were first acidified with trifluoroacetic acid (TFA), diluted 2-fold with 0.1% TFA, and loaded with syringe onto the Sep-pak solid-phase extraction material. After sample loading, the cartridges were washed with 0.1% TFA, and eluted with 60% acetonitrile with 0.1% TFA. Three sequential 0.5-mL elutions were carried out, and eluates were reduced to dryness using vacuum centrifugation.
Titanium dioxide enrichment of phosphopeptides
Phosphopeptides were enriched as previously described, but with minor modifications. 27 Purified tryptic peptides were resuspended in buffer A (0.5% heptafluorobutyric acid/2% acetonitrile [ACN]) containing 300 mg/mL lactic acid (buffer B). Thirty milligrams of Titanosphere TiO 2 5-μm beads (GL Sciences, Torrance, CA, USA) were placed in a 1.5-mL Eppendorf tube, where they were washed twice with buffer C (0.05% heptafluorobutyric acid/80% ACN), and then added to the resuspended tryptic peptides. The mixtures were rotated at room temperature for 30 min, centrifuged for 30 s at 5000 g, and the supernatant was discarded. The phosphopeptide-bound beads were washed with 500 μL buffer D (buffer C containing 300 mg/mL lactic acid) then twice with 500 μL buffer C. Phosphopeptides were eluted from the TiO 2 beads using 500 μL of 0.5 M ammonia and then twice with 500 μL of 5 M ammonia prior to drying by vacuum centrifugation. Each eluate was reconstituted in 0.1% formic acid to pH 3.0.
Liquid chromatography-electrospray ionization/tandem mass spectrometry analysis Peptides were loaded onto a self-packed biphasic C18/SCX multidimensional protein identification technology (MuDPIT) column using a helium-pressurized cell (pressure bomb). The MudPIT column consisted of 360 × 150 μm i.d. fused silica, which was fitted with a filter-end fitting (IDEX Health & Science, Middleboro, MA, USA) and packed with 6 cm Luna SCX material (5 μm, 100 Å) and 4 cm Jupiter C18 material (5 μm, 300 Å; Phenomenex, Torrance, CA, USA). Once the sample was loaded, the MuDPIT column was connected using an M-520 microfilter union (IDEX Health & Science) to an analytical column (360 μm × 100 μm i.d.), equipped with a laser-pulled emitter tip and packed with 20 cm of C18 reverse phase material (Jupiter, 3-μm beads, 300 Å; Phenomenex). Using an Eksigent NanoLC Ultra HPLC and Autosampler, MudPIT analysis was carried out with an 11-step salt pulse gradient (25, 50, 75, 100, 150, 200, 250 , 500, 750, and 1000 mM ammonium acetate). Peptides were eluted from the analytical column after each salt pulse with a 105-min reverse-phase solvent gradient (2-45% acetonitrile containing 0.1% formic acid) for the first 10 salt pulses, and a 105-min gradient of 2-95% acetonitrile containing 0.1% formic acid for the last salt pulse. Gradient-eluted peptides were introduced using nanoelectrospray into an LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). The data were collected using a six-scan event datadependent method. Full scan (m/z 400-2000) spectra were acquired with the Orbitrap as the mass analyzer (resolution 60 000), and the five most abundant ions in each mass spectrometry (MS) scan were selected for fragmentation in the LTQ. An isolation width of 2 m/z, activation time of 30 ms, and 35% normalized collision energy were used to generate MS/MS spectra. The MSn AGC target value was set to 1e, 4 and the maximum injection time was set to 100 ms. Dynamic exclusion was enabled, using a repeat count of 1 and an exclusion duration time of 60 ms.
Database searching and phosphopeptide scoring
Tandem mass spectra were analyzed using a suite of custom-developed bioinformatics tools. The MS/MS spectra were converted into DTA files and searched on a 2500-node Linux cluster supercomputer using a custom version of the Sequest algorithm 28 and compared to the UniProt human database (version 155; 31 December 2009) containing 83 946 protein sequences. Search parameters included a 2.5 Da precursor mass tolerance, digestion with trypsin (K/R), and variable modifications of carbamidomethylation of cysteine, oxidation of methionine residues, and phosphorylation of Ser, Thr, and Tyr residues. All search results were assembled with Scaffold (version 3.3.3; Proteome Software, Portland, OR, USA) where protein and peptide probabilities were calculated. Ascore values for phosphosite assignments were calculated in Scaffold PTM (version 1.1.3). A detailed list of all spectra, phosphopeptides, and phosphoproteins identified is provided (Data S1).
Determination of differential phosphosite abundance
Counts of MS/MS spectra assigned to a given phosphosite, inclusive of miscleaved phosphopeptides, were normalized to the length of the protein (number of amino acids) then against the sum of spectra in the sample, resulting in a normalized phosphosite spectral abundance factor (NPSAF). The NPSAFs observed in at least five of Phosphoproteomics of NAFLD 1471 Hepatology Research 2017; 47: 1469-1483 eight subjects in at least two cohorts were used for statistical testing. P-values were calculated using a Kruskal-Wallis test using GraphPad Prism (version 5.04; GraphPad, La Jolla, CA, USA). Significance was set at P < 0.05.
Mapping detected phosphopeptides to intracellular signaling pathways
We queried our data against the Phosphosite database, a curated bioinformatics resource housing information regarding 156 143 non-redundant phosphorylation sites as of June 2014 (http://www.phosphosite.org). We determined proteins displaying differentially abundant phosphorylation sites using Ingenuity Pathway Analysis (Mountain View, CA, USA) for identification of highly interconnected proteins. 29 The coverage of various biological pathways associated with the complete (NOR, SS, and NASH) phosphoprotein dataset was scored using Fisher's exact test and the highest scoring pathways were ranked by P-value. Kinase motif analysis was then carried out. 30 We then quantified phosphopeptide abundance and calculated NPSAFs. 25 Those NPSAFs observed in at least five subjects in a single cohort were used for statistical testing. P-values were calculated using a Kruskal-Wallis test using GraphPad Prism (version 5.04). Finally, NPSAFs were subjected to Pearson hierarchical clustering using average linkage clustering with MultiExperiment Viewer (version 4.8.0; http://www.tm4.org).
RESULTS
Anthropomorphic measurements
T HE PRESENCE OF steatosis, ballooning, inflammation, and fibrosis was determined by a hepatopathologist using two independent histologic specimens for classification and subsequent scoring by NAS. 26 Eight obese subjects from each cohort were selected. The NAFLD subjects were similar in terms of gender, ethnicity, body mass index, and fasting blood glucose. Subjects with NASH were slightly older (P < 0.001) than the NOR cohort (Table 1) .
Plasma aspartate aminotransferase, alanine aminotransferase, alanine aminotransferase/aspartate aminotransferase ratio, total bilirubin, albumin, and platelets were not significantly different among the three groups. However, plasma levels of alkaline phosphatase were elevated (P < 0.01) by nearly two-fold in both SS and NASH vs. NOR. Estimates of fibrosis were made by trichrome stain. Normal specimens were almost uniformly void of steatosis, inflammation, and fibrosis resulting in an overall NAS of 0.4 ± 0.2. The SS and NASH specimens had a mean NAS of 2.2 ± 0.1 and 5.0 ± 0.4, respectively Data presented as mean ± standard error of the mean. ALT, alanine aminotransferase; AST, aspartate aminotransferase, BMI, body mass index; NASH, non-alcoholic steatohepatitis; NAFLD, non-alcoholic fatty liver disease; simple steatosis, SS.
(P < 0.001). Details of individual patient biopsy NAS can be found in Table 2 .
Identification of human liver phosphoproteins
An overview of the workflow for phosphopeptide and phosphosite analyses is shown in Figure 1 . Using RP-nano liquid chromatography (LC)-electrospray ionization (ESI) MS/MS we identified 3532 unique phosphopeptides, corresponding to 3078 non-redundant sites on 1434 phosphoproteins. Over 70% of the identified phosphosites were present in the phosphosite database, indicating the reliability of our approach. A variable number of phosphopeptides and phosphorylation sites were identified in each of the 24 subjects, averaging 585 phosphopeptides and 445 sites per sample. Multiply phosphorylated peptides were frequently observed, consistent with reported enrichment strategies using TiO2. 31 Although the total number of phosphopeptide spectra identified was similar across the three cohorts (Fig. 2a) , phosphopeptides containing phosphoserine (pSer) were most abundant, followed by phosphothreonine (pThr) and phosphotyrosine (pTyr) (Fig. 2b) . Specimens in each histologic category generated similar numbers of total non-redundant phosphopeptides, indicating our enrichment strategy was not biased with regards to any particular sample group (1975 in SS and 2040 sites in NASH vs. 2080 in normal obese).
We generated Venn diagrams to illustrate shared and unique (shaded areas) phosphopeptides (Fig. 2c) , and phosphosites for each cohort (Fig. 2d) . Among the unique phosphosites found only in SS were fibrinogen α chain (FGA) Ser364, serine/arginine repetitive matrix2 (SRRM2) Thr1003, and serine/threonine-protein kinase Wnk1 (WNK1) Ser2032. Differentiating NASH were EH domain binding protein 1 (EHBP1) Ser1058, filamin1 (FMN1) Ser1031, PEST proteolytic signal-containing nuclear protein (PCNP) Ser119, and plasminogen activator inhibitor 1 RNA-binding protein (SERBP1) Ser25. These contrast with the presence of several phosphosites in livers obtained from the NOR cohort; these include cAMPdependent protein kinase type II-β regulatory subunit (PRKAR2B Ser114), regulator of cohesion maintenance, homolog B (PDS5B) Ser1394, protein tyrosine phosphatase-like A domain containing 1 (PTPLAD1) Am, American; BMI, body mass index; F, female; NASH, non-alcoholic steatohepatitis; SS, simple steatosis.
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Ser114, and protein kinase, AMP-activated, γ2 noncatalytic subunit (PRKAG2) Ser157.
Relative quantification of detected phosphorylation sites on enriched peptides
Determinations of relative phosphosite abundance were made using spectral counting as described. [32] [33] [34] Reproducibility of the NPSAF applied to TiO 2 -enriched phosphopeptides was facilitated by comparing phosphopeptide profiles from three separate portions of human liver extract from a single individual, independently digested with trypsin, enriched for phosphopeptides, and processed for MuDPIT. Using linear regression, we observed strong agreement among the abundance measurements of 348 phosphopeptides common to all three sample replicates (r 2 = 0.815 for Figure 1 Workflow of sample preparation and data analysis. (a) Obese subjects were subjected to wedge liver biopsy (100-200 mg) during elective Roux-en-Y gastric bypass surgery. Specimens were scored as normal (NOR), simple steatosis (SS), or non-alcoholic steatohepatitis (NASH) (n = 8/cohort) using the non-alcoholic fatty liver disease activity score. Combining and collapsing the results from all 24 volunteers allowed identification of 1134 phosphopeptides bearing 967 phosphorylation sites that were common among cohorts (Data S1). Phosphosites that were assigned in at least five of eight subjects (majority) in any group totaled 343 (Data S4); these were used for relative quantitative analyses and identified a total of 12 that were significantly (P < 0.05) different among the three groups using one-way ANOVA (Table 3) . We used the Kruskal-Wallis test to analyze the data due to nonhomogenous NPSAF variances for over half of the proteins analyzed. Of the 12 phosphorylation sites that significantly differed by ANOVA, eight differed significantly by KruskalWallis, including DNA-binding phosphoproteins such as serine/arginine repetitive matrix protein1 (SRRM1 Ser616) and Yes-associated protein 1 (YAP1 S109) increased with worsening NAFLD severity. Two phosphosite NPSAFs, those for chromobox homolog 3 (CBX3 Ser95) and nuclear ubiquitous casein and cyclindependent kinases substrate1 (NUCKS1 Ser79), were decreased in subjects with NASH. Amyloid βA4 precursor protein-binding family A1 and putative uncharacterized protein MATR3 Ser188 showed bimodal patterns of NPSAF-determined phosphosite abundance, with values lowest (APBA1 Ser263) or greatest (MATR3 Ser188) in SS specimens.
Differential phosphoprotein expression networks in NAFLD
Specimens were grouped by similarities in NPSAFs. The relatedness of the relative abundance of the shared phosphosites is indicated by the dendrogram in Figure 3 . The length and subdivision of the branches display the relatedness of the liver specimens (top) and NPSAF (left). Hierarchical clustering was able to distinguish liver specimens in two groups (first branch divisions on top). The first group was composed primarily of NOR and SS specimens with only two NASH specimens. Six of the eight NASH specimens along with three NOR and two SS clustered in the second group. Broadly speaking, group 1 was dominated by mostly lower NPSAFs (darker blue/teal colors), whereas group 2 displayed increased NPSAFs (red/yellow colors). Taken together, these data suggest a pattern of phosphopeptide activation/deactivation consistent with the development of NASH rather than an isolated aberrant pathway.
In order to predict the differential activity of kinases in NOR, SS, and NASH specimens, we grouped phosphosites based on known kinase consensus motifs present in each phosphopeptide primary amino acid sequence. Table 4 shows the percentage of assigned phosphopeptide spectra for NOR, SS, and NASH cohorts matching one of 30 described kinase motifs. Overall, there were no significant differences in the abundance levels of phosphopeptides.
Heat shock protein 27kD (HSPB1) S78 differential phosphorylation abundance with increasing NAFLD severity
To establish the expression levels of differentially detected phosphorylation sites, we carried out immunoblot analyses on a subset of samples for which additional material was available. Commercially available phosphospecific and total antibodies were identified for only one of the detected phosphorylation sites, heat shock 27-kD protein 1 (HSPB) Ser78. In concordance with our phosphoproteomics profiling results, densitometric analysis of a 27-kD band recognized in each liver protein homogenate confirmed the profiling results (Data S5) with the trend of increased phosphorylation of HSPB1 Ser78 persisting in the NASH specimens.
DISCUSSION
I N THIS STUDY, we used a quantitative
phosphoproteomic technique to analyze human liver samples with a histologic diagnosis of NOR, SS, or NASH. We used an NPSAF approach to gauge relative differences in phosphosite abundance among all liver samples and used bioinformatics approaches to understand the implications of differences in phosphosite abundance at both the single protein and pathway level. Importantly, the patterns of liver protein phosphorylation site abundance we identified were able to discriminate the histopathologic relatedness of six out of eight SS specimens and six out of eight NASH specimens (Fig. 3) . These patterns were suggestive of defects in canonical pathways of carbohydrate metabolism as well as RNA post-transcriptional modifications, gastrointestinal disease, cell-cell signaling, and cancer. Several different reports of whole liver phosphoproteomes 35, 36 and subfractions (e.g. mitochondria and cell lines) [37] [38] [39] [40] have been reported in mice, but only a handful of studies have used human liver, [41] [42] [43] [44] [45] [46] almost all from subjects of Asian descent. [42] [43] [44] 46 Our findings identified several phosphorylation differences in both homeostatic and disease-specific processes and highlight the utility of phosphoproteomic profiling, leading to the development of novel targeted therapeutic approaches for NASH. 47, 48 In order to determine the biologic relevance of our findings, we subjected our phosphoproteins to Ingenuity Pathway Analysis (www.ingenuity.com). Canonical signaling pathways associated with the entire detected liver phosphoprotein dataset was scored using Fisher's exact test and the highest scoring (best covered) pathways were ranked by P-value (Fig. 4a) . Carbohydrate metabolism and gastrointestinal disease (Data S6) received the highest scores followed by RNA post-transcriptional modification (Data S7), cell-cell signaling (Data S8), lipid metabolism (Data S9), and cancer (Data S10). We selected carbohydrate metabolism to explore the relationships among detected phosphoproteins (Fig. 4b,c) . Thirty-five proteins comprise this pathway, with different node shapes shown in Figure 4 (b) (diamonds, ovals, or rectangles) denoting the functional classification of the proteins. Forty-nine of the phosphosites we measured, mapping to 29 phosphoproteins, were present on this pathway and include binding proteins (CDC42EP1), translational and transcriptional regulators (EEF1D, SRRM1, SRRM2, and PEBP1) and enzymes (ALDOA, ALDOC, GAPDH, ERCC5, PDI1, and XRN2) (Fig. 4b) . When comparing expression differences in the NPSAF values of these phosphosites between NOR and SS specimens, four phosphosites (shades of red) were increased in abundance while 32 phosphosites (shades of green) were decreased. A different pattern of phosphosite abundance was noted when comparing Figure 3 Hierarchical clustering of 24 nonalcoholic fatty liver disease liver specimens by normalized phosphosite spectral abundance factor (NPSAF). Fold change heat map (À2.0 to 2.0-fold) by NPSAF based across histologically normal, simple steatosis, and non-alcoholic steatohepatitis specimens (top). NPSAFs for each sample were log transformed and scaled to the average detected value (defined as 0). Saturated red color indicates at least a twofold increase in mean levels of phosphopeptide NPSAF; saturated blue color indicates a two-fold decrease in mean levels of phosphosite NPSAF. [Color figure can be viewed at wileyonlinelibrary.com] NASH and SS specimens. There was a modest increase in NPSAF abundance noted for sites such as PDCD5 Ser119, PDLIM2 Ser124, Ser134, and Ser197 and PEBP1 Ser52. Certain phosphosites, such as CDC42EP1 Ser121, increased over 3.8-fold, while five others such as KTN1 Ser75, LSP1 Ser189, SRRM1 Ser616, SRRM2 Ser1083 and TRAFD1 Ser327 increased over 2-fold in NASH versus SS specimens (Fig. 4c) . This differential activation of signaling networks in NASH and SS versus NOR specimens suggests a central role for these carbohydrate metabolism phosphosites in mediating the disease processes driving the development of NASH. These are consistent with recent findings examining the role of polymorphisms in patatin-like phospholipase domain containing3 (PNPLA3), strongly associated with NAFLD in humans, 49 which showed that excess carbohydrate relative to fat potently regulates PNPLA3. 50 More work is needed to fully understand how aberrant carbohydrate metabolism drives NAFLD progression.
RNA post-transcriptional modification is another canonical pathway identified as important in our analyses. These findings are noteworthy given the significant increase of HSPB1 (Hsp27) Ser78 we identified (Data S9) and given its known role in the regulatory sequence AU-rich element-mediated mRNA decay. 51 Tian et al. recently showed in a phosphoproteomic study of hepatocellular carcinoma that proteins in the spliceosome pathway were important for regulating mRNA processing and RNA splicing. 45 In our study, heterogeneous nuclear ribonucleoproteins C, D, K, and U, known to bind to pre-mRNA, were among the phosphoproteins mapped to this pathway, and may be associated with the splicing apparatus. 52 In comparison with other available phosphorylation sites in NAFLD, Younossi and colleagues recently examined phosphoproteomic biomarkers in visceral adipose tissue to characterize the predictive value of a predetermined panel of phosphorylation sites in diagnosing NASH and related fibrosis. 24 Their best Column values indicate the number of spectra (percentage of total phosphopeptide spectra per category) observed for each motif. NASH, nonalcoholic steatohepatitis; NOR, normal; SS, simple steatosis.
performing model relied on levels of the phosphorylation of GSK3B Tyr279 as well as phosphosites on two subunits of c-AMP regulated protein kinase Cα (PKC) Thr197 and protein kinase Cβ (catalytic subunit) Thr638/641. In our study, we did not see such trends, suggesting that protein phosphorylation in visceral adipose and liver tissues may be inherently different in signaling networks involved in NASH. This study has limitations, the most important of which relates to the small sample size of class III obese subjects; hence, our findings may not apply to class I or II obese patients. Additionally, subjects with NASH were older, which we acknowledge may be an independent source of phosphoproteomic differences between NASH and other cohorts. Yet despite these limitations, an identifiable, modified HSP27 Ser78 emerged as a site of interest. Heat shock protein 27 serves several diverse functions: in regulating mRNA decay, mRNA stabilization, 53 inhibition of apoptosis, 54 and modulation of actin polymerization. 55, 56 Serine 78 serves as one of three different phosphorylation sites in HSP27 (the others being Ser15 and Ser78) that are phosphorylated by mitogenactivated protein kinase-activated protein kinase 2.. 57 Phosphorylation of HSP27 is usually associated with the disassembly of HSP27 complexes 58 and has been correlated with functions such as cell migration 59 and with stress protection. 60 Recent reports showed that HSP27 Ser78 phosphorylation was essential to TRAIL-triggered Src-Akt/ERK signaling, possibly serving as a survival signaling mechanism. 61 In summary, we have provided an expansive and as yet undescribed view of human liver phosphorylation in the context of an increasingly prevalent disease. Our data paint a highly complex picture of protein signaling in human liver and suggest a shift in kinase abundance and activity in NASH. Furthermore, our findings delineate site-specific alterations in NAFLD and NASH and provide a previously unavailable catalog of abundant phosphorylated proteins in human liver. Taken together with emerging loci of interest from genomic studies in NAFLD, these data should serve as a basis for the generation of novel hypotheses concerning the precise molecular mechanisms discriminating SS from NOR and NASH. As instrumentation and bioinformatics tools improve, [62] [63] [64] the understanding of these and other phosphorylated protein relationships to specific aspects of NAFLD pathophysiology will increase, thereby providing new therapeutic targets.
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